---
title: "ZZPZH's subsidiary plans to invest 200 million yuan in the GaoXin RunXin Fund"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251828825.md"
description: "ZZPZH announced that its wholly-owned subsidiary plans to invest 200 million yuan using its own or raised funds to participate in the investment of Zhangzhou Gaoxin Runxin Health Industry Investment Partnership (tentative name). The fund aims to raise 1 billion yuan, primarily investing in the medical and health field, including pharmaceuticals, medical devices, and related supply chains, with investments outside the medical and health sector not exceeding 10%"
datetime: "2025-08-06T11:50:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251828825.md)
  - [en](https://longbridge.com/en/news/251828825.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251828825.md)
generator: "portal-rs"
---

# ZZPZH's subsidiary plans to invest 200 million yuan in the GaoXin RunXin Fund

According to the announcement from Zhitong Finance APP, Pianzaihuang (600436.SH) has stated that the company is actively seeking new growth points based on the upstream and downstream considerations of the big health industry chain, enhancing industrial synergy effects, and improving sustainable competitive capabilities while ensuring the development of its main business. The company plans to invest in Zhangzhou Gaoxin Runxin Big Health Industry Investment Partnership (Limited Partnership) (tentative name, subject to industrial and commercial registration; referred to as "Gaoxin Runxin Fund"). The target fundraising scale for this Gaoxin Runxin Fund is 1 billion yuan. The company's wholly-owned subsidiary, Pianzaihuang Investment, intends to act as a limited partner and contribute 200 million yuan using its own or self-raised funds, accounting for 20% of the Gaoxin Runxin Fund's target fundraising scale.

The main investment areas of the fund are in the medical and health sector, including pharmaceuticals, medical devices, upstream supply chains and components for medical health, health food and supplements, synthetic biology, chemical materials, consumer healthcare, and other big health-related fields. Investments in areas outside of medical and health will not exceed 10% of the fund's subscribed capital contribution scale

### Related Stocks

- [600436.CN](https://longbridge.com/en/quote/600436.CN.md)

## Related News & Research

- [iFX EXPO Asia 2026: Hong Kong Set to Welcome 5,000+ Global Trading and Fintech Professionals This October](https://longbridge.com/en/news/297501037.md)
- [Kyntra Bio CEO presents at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/297778123.md)
- [XPENG Sales Up 4% in August](https://longbridge.com/en/news/297713940.md)
- [Xiaomi sets September 7 launch for 18 Fold foldable phone](https://longbridge.com/en/news/297748864.md)
- [Schmid Group CFO Arthur Schuetz acquires 15,200 shares for $49,096](https://longbridge.com/en/news/297505737.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**